期刊文献+

消癌平注射液联合XELOX方案化疗对晚期结直肠癌患者近期增效减毒作用 被引量:10

Recent synergistic and attenuated effects of Xiao-Ai-Ping injection combined with XELOX regimen in patients with advanced colorectal cancer
原文传递
导出
摘要 目的观察消癌平注射液联合XELOX方案治疗晚期结直肠癌的疗效及不良反应。方法选取2015年4月至2016年10月确诊的晚期结直肠癌患者82例,按治疗方法分为两组,XELOX组应用XELOX方案化疗(n=36),消癌平+XELOX组应用消癌平注射液联合XELOX方案化疗(n=46),治疗过程中观察患者化疗不良反应,并于治疗2个周期后进行疗效评价。结果 XELOX组患者有效率为44.4%,消癌平+XELOX组有效率为67.4%,两组治疗有效率差异有统计学意义(P<0.05)。依据KPS评分标准,消癌平+XELOX组患者生活质量改善情况明显优于XELOX组(P<0.05)。消癌平+XELOX组的白细胞降低、恶心、呕吐、神经毒性明显低于XELOX组(P均<0.01)。结论消癌平联合XELOX方案化疗较单纯XELOX方案化疗可明显提高近期化疗效果,改善患者生活质量,减少毒副反应,具有增效减毒的作用。 Objective To observe the clinical efficacy and adverse reactions of Xiao-Ai-Ping injection combined with XELOX regimen in the treatment of advanced colorectal cancer. Method Eighty-two patients with definite diagnose of advanced colorectal cancer from April 2015 to October 2016 were recruited in this study and divided into control group and case group. Capecitabine combined with oxaliplatin(XELOX) regimen was performed in control group(n = 36),and XiaoAi-Ping injection was added based on XELOX regimen in case group(n = 46). The adverse reaction was observed during chemotherapy,and the curative effect was evaluated after 2 cycles of treatment. Results The effective rate in case group was significantly higher than that in control group(67. 4% vs 44. 4%,P〈0. 05). According to the Karnofsky performance status(KPS) score,the quality of life in case group was significantly better than that in control group(P〈0. 05). The incidence rates of leukocyte reduction,nausea,vomiting and neurotoxicity in case group were significantly lower than those in control group(P〈0. 01). Conclusion The chemotherapy of Xiaoping combined with XELOX regimen can obviously increase the short-term curative effect of chemotherapy,improve the patient's life quality,reduce the side reactions and have the effect of increasing the efficiency and reducing the toxicity.
作者 万晓龙 郑彩霞 王亚利 林帅 董水滢 WAN Xiao-long;ZHENG Cai-xia;WANG Ya-li;LIN Shuai;DONG Shui-ying(Department of Gastroenterology,The Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shaanxi 710004,China)
出处 《中国临床研究》 CAS 2018年第8期1072-1074,共3页 Chinese Journal of Clinical Research
关键词 晚期结直肠癌 消癌平 化学疗法 XELOX方案 毒副反应 Advanced colorectal cancer Xiao-Ai-Ping Chemothera peutic XELOX regimen Toxic and adversereaction
  • 相关文献

参考文献7

二级参考文献103

  • 1方茵,田少雷,李克庆,赵树纬,王志远.抗肿瘤药物研究Ⅱ:去甲斑蝥素去氧脱氢类似物的合成与抗癌活性[J].药学学报,1993,28(12):931-935. 被引量:166
  • 2张汝,侯建梅.抗血管化疗及研究进展[J].中国肿瘤临床与康复,2007,14(3):265-268. 被引量:5
  • 3李凯,邹华伟.消癌平联合化疗治疗晚期食管癌的临床观察[J].中华肿瘤防治杂志,2007,14(16):1272-1273. 被引量:28
  • 4李东,欧阳建,李翠萍,陈军浩.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250. 被引量:36
  • 5Cats A. New development in systemic chemotherapy in advanced colorectal cancer [J]. Seand J Gastroenterol Suppl, 2003, (239) : 78-86. 被引量:1
  • 6The Advanced Colorectal Cancer MetaAnalysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate [J]. J Clin Oncol, 1992,10(6) : 896-903. 被引量:1
  • 7Poon M A, O'Connell M J, Wieand H S, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer [J]. J Clin Oncol, 1991,9(11):1967- 1972. 被引量:1
  • 8de Gramont A, Bosset J F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluoronracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study [J]. J Clin Oncol, 1997,15(2): 808-815. 被引量:1
  • 9Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase Ⅱ studies of oxaliplatin (LOHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluorepyrimidines [J]. Ann Oncol, 1996,7( 1 ) :95-98. 被引量:1
  • 10Becouarn Y, Ychou M, Ducreux M, et al. Phase H trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers [J]. J Clin Oncol, 1998,16 ( 8 ) : 2739-2744. 被引量:1

共引文献109

同被引文献240

引证文献10

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部